Navigation Links
Risks in multiple pregnancies
Date:10/8/2010

The complication rate during pregnancy with twins is about 40%. Women with multiple pregnancies often develop pre-eclampsia, gestational diabetes, and hemorrhages during the term of their pregnancy. Joachim W Dudenhausen from the Charit Berlin University Medicine and Rolf F Maier from Magdeburg University Medical Center, investigate which risks can be minimized by close monitoring in multiple pregnancies (Dtsch Arztebl Int 2010; 107[38]: 663-8).

14 in 1000 pregnancies will be multiple pregnancies. The average term for multiple pregnancies is notably shorter (for twins, 36 weeks; for triplets, 32 weeks; and for quadruplets, 30 weeks). Causes include the greater weight carried by the pregnant woman and increased metabolism compared with a pregnancy with only one fetus. In monozygotic twins, only one placenta is present; consequently, the risk of death of one twin is higher than in dizygotic twins, where two placentas are present.

The feto-fetal transfusion syndrome affects only monozygotic twins and results in an undersupply of blood in one twin. The cause is a connecting blood vessel between the embryos, which leads to a redistribution of the blood. The treatment of choice for the syndrome is coagulation of the connecting vessel. The growth of the fetuses needs close monitoring. The fetal growth curves of head diameter and length of femur in twins are no different from those in singletons, but towards the end of multiple pregnancies, intrauterine growth is delayed. For this reason, in multiple pregnancies the delivery should be arranged after the 38th completed week of gestation.


'/>"/>

Contact: Joachim Dudenhausen
Joachim.Dudenhausen@charite.de
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related biology news :

1. Ben-Gurion University of the Negev researchers identify risks of hypertension in young adults
2. Gender-specific disease risks start in the womb
3. Payment Default Risks Remain a Crucial Issue for Businesses Across Europe
4. $3.7 million trial uses genes to balance risks, benefits of blood thinner
5. To close achievement gap, US must address major health risks for urban minority youth, study finds
6. Epigenetics could help researchers determine any risks associated with low-dose radiation
7. Crucial differences found among Latino populations facing heart disease risks
8. Report documents the risks of giant invasive snakes in the US
9. Risks involved with transgenic fish
10. Preimplantation genetic diagnosis may pose neurological risks
11. Climate change: Global risks, challenges and decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... in French . , Prof. Claudio Cuello at ... can emulate Alzheimer,s disease in humans, enabling research that will ... brain condition leading to a progressive decline of memory and ... in the past, rats are more intelligent than other rodents ...
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-03/sfeb-ftc032910.php,">Chinese ... known antiepileptic agent widely used throughout the world. ... have suggested that, as for other anticonvulsant drugs ... including valproate and carbamazepine, phenytoin may have mood-stabilizing ...
... Helmholtz Zentrum Mnchen has launched a new cooperative project ... therapeutic approaches against lymphoid tumors. With a two-year grant ... two partners will seek to further develop lentiviral vector ... cancer form and to devise approaches for treatment. ...
Cached Biology News:From the clinics to the bench and back -- phenytoin as a mood stabilizer? 2Development of new anti-cancer gene therapy approach using lentiviral vectors 2
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... ... that have $1 - $20 million in yearly revenues and have experienced significant growth over ... , ... September 24, 2009 -- Orange County has become a hub for innovation and growth and ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a new market ... World Market for Cancer Therapeutics and Biotherapeutics, 3rd. ... http://www.reportlinker.com/p0119229/World-Market-for-Cancer-Therapeutics-and-Biotherapeutics-3rd-Edition-The.html , , ... year. This number is expected to increase by 2.4% by 2020 ...
... , , WAYNE, ... Bonatti, M.D., Professor of Surgery and Director of Coronary Surgery ... Center in Baltimore, has completed the world,s first use of ... robotic and fully endoscopic heart surgery. The new cardiopulmonary bypass ...
Cached Biology Technology:Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 11MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4
Without sodium bicarbonate. Sterile, Cell culture tested...
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Open Frame DNAscope is an integrated confocal ... and readily integrated into your specific application. ... we can tailor the system to your ... optical scanning design has been modularized and ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
Biology Products: